Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Entrectinib, a new multi-target inhibitor for cancer therapy
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 47
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 36
Nerve Growth Factor and the Role of Inflammation in Tumor Development
Giampiero Ferraguti, Sergio Terracina, Luigi Tarani, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 2, pp. 965-989
Open Access | Times Cited: 17
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
Xianbo Wu, Jie Wang, Qi Liang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113116-113116
Open Access | Times Cited: 41
Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7
Xiangyu Jin, Didi Liu, Xinru Zhou, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 12, pp. 101310-101310
Open Access | Times Cited: 25
In vitro biological studies and computational prediction-based analyses of pyrazolo[1,5-a]pyrimidine derivatives
Abdulrahman A. Almehizia, Wael M. Aboulthana, Ahmed M. Naglah, et al.
RSC Advances (2024) Vol. 14, Iss. 12, pp. 8397-8408
Open Access | Times Cited: 15
Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study
Noura F.M. El Hamaky, Abdelrahman Hamdi, Waleed A. Bayoumi, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107437-107437
Closed Access | Times Cited: 13
New Approaches Towards Targeted Therapy for Childhood Neuroblastoma
Tina Dalianis, Monika Lukoseviciute, Stefan Holzhauser, et al.
Anticancer Research (2023) Vol. 43, Iss. 9, pp. 3829-3839
Open Access | Times Cited: 17
Repurposing FDA-approved compounds to target JAK2 for colon cancer treatment
Bavya Chandrasekhar, Ravi Gor, Satish Ramalingam, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Fluorinated azoles as effective weapons in fight against methicillin-resistance staphylococcus aureus (MRSA) and its SAR studies
Xuanming Zhao, Rameshwari Verma, M. B. Sridhara, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 106975-106975
Closed Access | Times Cited: 14
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
Maria Novella Romanelli, Laura Braconi, Alessio Gabellini, et al.
Molecules (2023) Vol. 29, Iss. 1, pp. 68-68
Open Access | Times Cited: 13
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis
Zhiwei Cui, Zhen Zhai, De Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Milan Beljkaš, Aleksandra Ilić, Alen Cebzan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2581-2581
Open Access | Times Cited: 11
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy
Yue Shen, Jie-Qi Chen, Xiangping Li
Genes & Diseases (2024) Vol. 12, Iss. 3, pp. 101374-101374
Open Access | Times Cited: 4
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Integrated non-targeted metabolomics and gut microbial systematic analysis the mechanism of anti-tumour activity of Poriae Cutis-derived lanostane triterpenes in vivo
Shuai Yue, Xi Feng, You‐Sheng Cai, et al.
Food Bioscience (2025), pp. 105978-105978
Closed Access
Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways
Qi Tang, Jiahong Dong, Feng Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Design, synthesis, biological evaluation, and in silico study of quinazoline-based dual inhibitors targeting EGFR and VEGFR-2 for cancer therapy
Ali Altharawi, Manal A. Alossaimi, Taibah Aldakhil
Arabian Journal of Chemistry (2025), pp. 1-8
Open Access
Discovery of Genomic Targets and Therapeutic Candidates for Liver Cancer Using Single-Cell RNA Sequencing and Molecular Docking
B.N. Biswas, Masahiro Sugimoto, Md. Aminul Hoque
Biology (2025) Vol. 14, Iss. 4, pp. 431-431
Open Access
Optimizing Entrectinib Nanosuspension: Quality by Design for Enhanced Oral Bioavailability and Minimized Fast-Fed Variability
S. Sreenivasa Chary, D. V. R. N. Bhikshapathi, N. Mohana Vamsi, et al.
BioNanoScience (2024) Vol. 14, Iss. 4, pp. 4551-4569
Closed Access | Times Cited: 3
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical
Yichao Kong, Caihong Jiang, Guifeng Wei, et al.
Molecules (2023) Vol. 28, Iss. 12, pp. 4672-4672
Open Access | Times Cited: 8
Identification of Hub of the Hub-Genes From Different Individual Studies for Early Diagnosis, Prognosis, and Therapies of Breast Cancer
Md Shahin Alam, Adiba Sultana, Md. Kaderi Kibria, et al.
Bioinformatics and Biology Insights (2024) Vol. 18
Open Access | Times Cited: 2
A review on tyrosine kinase inhibitors for targeted breast cancer therapy
Vidya Sankarapandian, Ramya Lakshmi Rajendran, Conrad Ondieki Miruka, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155607-155607
Closed Access | Times Cited: 2
Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment
Xuelan Gan, Handong Wang, Jianguo Luo, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 192, pp. 106624-106624
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top